Merck
CN
  • Mutation spectrum of RB1 gene in unilateral retinoblastoma cases from Tunisia and correlations with clinical features.

Mutation spectrum of RB1 gene in unilateral retinoblastoma cases from Tunisia and correlations with clinical features.

PloS one (2015-01-21)
Hajer Ayari-Jeridi, Kimberly Moran, Amel Chebbi, Hédi Bouguila, Imen Abbes, Khaoula Charradi, Amel Benammar-Elgaaïed, Arupa Ganguly
摘要

Retinoblastoma, an embryonic neoplasm of retinal origin, is the most common primary intraocular malignancy in children. Somatic inactivation of both alleles of the RB1 tumor suppressor gene in a retinal progenitor cell through diverse mechanisms including genetic and epigenetic modifications, is the crucial event in initiation of tumorigenesis in most cases of isolated unilateral retinoblastoma. We analyzed DNA from tumor tissue and from peripheral blood to determine the RB1 mutation status and seek correlations with clinical features of 37 unrelated cases of Tunisian origin with sporadic retinoblastoma. All cases were unilateral except one who presented with bilateral disease, in whom no germline coding sequence alteration was identified. A multi-step mutation scanning protocol identified bi-allelic inactivation of RB1 gene in 30 (81%) of the samples tested. A total of 7 novel mutations were identified. There were three tumors without any detectable mutation while a subset contained multiple mutations in RB1 gene. The latter group included tumors collected after treatment with chemotherapy. There were seven individuals with germline mutations and all presented with advanced stage of tumor. There was no difference in age of onset of RB based on the germline mutation status. Thus 20% of the individuals with sporadic unilateral RB in this series carried germline mutations and indicate the importance of genetic testing all children with sporadic retinoblastoma. These findings help to characterize the spectrum of mutations present in the Tunisian population and can improve genetic diagnosis of retinoblastoma.

材料
货号
品牌
产品描述

Sigma-Aldrich
氯仿, contains 100-200 ppm amylenes as stabilizer, ≥99.5%
Sigma-Aldrich
氯仿, anhydrous, ≥99%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
氯仿, anhydrous, contains amylenes as stabilizer, ≥99%
Sigma-Aldrich
苯酚, puriss. p.a., ACS reagent, reag. Ph. Eur., 99.0-100.5%
Sigma-Aldrich
苯酚 溶液, Equilibrated with 10 mM Tris HCl, pH 8.0, 1 mM EDTA, BioReagent, for molecular biology
Sigma-Aldrich
氯仿, contains ethanol as stabilizer, ACS reagent, ≥99.8%
Supelco
苯酚, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
液状苯酚, ≥89.0%
Sigma-Aldrich
苯酚, for molecular biology
Sigma-Aldrich
苯酚 溶液, Saturated with 0.1 M citrate buffer, pH 4.3 ± 0.2, BioReagent, for molecular biology
Sigma-Aldrich
苯酚, ≥99%
Sigma-Aldrich
氯仿, ACS spectrophotometric grade, ≥99.8%, contains 0.5-1.0% ethanol as stabilizer
Sigma-Aldrich
氯仿, contains amylenes as stabilizer, ACS reagent, ≥99.8%
Sigma-Aldrich
苯酚, contains hypophosphorous as stabilizer, loose crystals, ACS reagent, ≥99.0%
Sigma-Aldrich
苯酚, BioXtra, ≥99.5% (GC)
Sigma-Aldrich
苯酚, puriss., ≥99.5% (GC), meets analytical specification of Ph. Eur., BP, USP, crystalline (detached)
Sigma-Aldrich
苯酚, natural, 97%, FG
Supelco
氯仿, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
苯酚, unstabilized, ReagentPlus®, ≥99%
Sigma-Aldrich
苯酚, puriss., meets analytical specification of Ph. Eur., BP, USP, 99.5-100.5% (GC)
Supelco
氯仿, analytical standard
Supelco
苯酚 溶液, certified reference material, 500 μg/mL in methanol
Sigma-Aldrich
苯酚, BioUltra, for molecular biology, TE-saturated, ~73% (T)
USP
苯酚, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
苯酚, ≥96.0% (calc. on dry substance, T)
Supelco
苯酚 溶液, 5000 μg/mL in methanol, certified reference material
Supelco
苯酚, PESTANAL®, analytical standard
Supelco
残留溶剂-氯仿, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
氯仿, ≥99%, PCR Reagent, contains amylenes as stabilizer
Sigma-Aldrich
苯酚, unstabilized, purified by redistillation, ≥99%